{
    "nct_id": "NCT05747794",
    "official_title": "AIPAC-003 (Active Immunotherapy and PAClitaxel): a Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (soluble LAG-3) in HER2-neg/low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization",
    "inclusion_criteria": "* Metastatic HR+ positive (estrogen receptor positive and/or progesterone receptor positive) or hormone receptor negative (HR˗), and HER2-neg breast adenocarcinoma, histologically proven by biopsy on the last available tumor tissue\n* Participants with HR+ metastatic breast cancer (MBC) who progressed on or after ≥1 line of endocrine based therapy and are indicated to receive chemotherapy for metastatic disease\n* Participants with HR- MBC (i.e. triple-negative breast cancer [TNBC]) who are indicated to receive paclitaxel chemotherapy without PD 1/PD-L1 therapy in the 1st line setting for metastatic disease\n* ECOG performance status 0-1\n* Expected survival longer than three months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior chemotherapy for metastatic breast adenocarcinoma\n* Participants with HR+ MBC who have received <1 line of ET based therapy in the metastatic setting\n* Participants with HR+ MBC who are not primary or secondary resistant to ET-based therapy and would be candidates to ET based therapy as per applicable treatment guidelines\n* TNBC participants who are candidates for PD-1/PD-L1 therapy in combination with chemotherapy\n* Disease-free interval of less than twelve months from the last dose of adjuvant chemotherapy",
    "miscellaneous_criteria": ""
}